A cancer that can develop anywhere in the body is sarcoma. Sarcomas disease is an uncommon type of cancer that appears in soft tissues and bones. About 12,000 soft tissue sarcomas and 3,000 bone sarcomas are diagnosed in the United States annually, according to the National Cancer Institute (NCI). In the UK, 15 new cases of sarcoma are diagnosed every day. That's almost 5,300 individuals annually. Soft tissue sarcoma (STS) and bone sarcoma (BS), also referred to as primary bone malignancy, are two of the over 100 molecular subtypes of sarcoma that have been identified due to its diverse character. [1]
Common types of Sarcoma
The most common varieties of STS are liposarcoma, leiomyosarcoma, and undifferentiated pleomorphic sarcoma (UPS), while the most common types of BS are osteosarcoma, chondrosarcoma (CS), and Ewing sarcoma (ES). There are over 70 histologic subtypes known to exist. Any age can be affected by sarcoma. Although it is more prevalent in middle-aged or older adults, it is the third most frequent cancer in youngsters. BS is most commonly reported in children and STS being more common in adults. Sarcoma accounts for about 1% of all cancer diagnoses in the United States. [2]
Signs of Sarcoma
A developing or shifting lump is the most typical sign of sarcoma. Additional symptoms may include stomach pain, nausea, loss of appetite or feeling full after a small quantity of food, blood in your stool or vomit, and bone swelling, soreness, or pain that may be worse at night. The cause of sarcomas is not supported by any evidence. [3]
Risk factor associated with Sarcoma
To completely comprehend how sarcoma develops, more research is required. Although sarcoma can strike at any age, there are a few factors that can raise the risk as we age. As with other cancers, sarcoma risk rises with age. Certain uncommon genetic abnormalities may raise your risk of developing sarcoma. Examples include Li-Fraumeni syndrome and neurofibromatosis. Rarely, years after receiving radiation treatment for another kind of cancer, some patients may develop STS. Chemical exposure has been linked to higher incidences of STS. These chemicals include vinyl chloride, dioxins, and phenoxyacetic herbicides. Bone disorder as Paget's disease is one illness that can raise the chance of BS. [4]
Current treatment to Sarcoma
Patients with resectable sarcoma are initially treated with surgery, but advanced sarcoma (unresectable) necessitates other treatments. For unresectable or metastatic STS, conventional chemotherapy (CT) is currently the accepted standard of care. While other cytotoxic medications are typically employed in subsequent lines (gemcitabine plus docetaxel, trabectedin, eribulin, or dacarbazine), anthracycline-based regimens, typically adriamycin plus ifosfamide, continue to be the initial treatment. Anaplastic lymphoma kinase (ALK) inhibitors for myofibroblastic tumors with ALK fusions, cediranib for alveolar soft part sarcoma (ASPS), and multi-TKI pazopanib for non-adipocytic STS are among the oral tyrosine–kinase inhibitors (TKI) that have also shown activity for STS. It is advised to treat BS using a multimodal approach that includes CT, radiation therapy (RT), and radical surgery. Preoperative CT combined with a MAP regimen (doxorubicin, cisplatin, and high-dose methotrexate) is typically the first line of treatment for young patients with high-grade osteosarcoma. Conventional CT with ifosfamide or cyclophosphamide plus...
(All Rights Reserved)